Key result
BNP and NT-proBNP are evaluated to determine which peptide is the better choice for the early clinical diagnosis of heart failure.
Why the study?
Does B-type natriuretic peptide (BNP) or N-terminal-proBNP (NT-proBNP) provide a better choice for the diagnosis of heart failure?
Does B-type natriuretic peptide (BNP) or N-terminal-proBNP (NT-proBNP) provide a better choice for the diagnosis of heart failure?
This paper discusses whether BNP or NT-proBNP is the better choice for diagnosing heart failure.
Neither BNP nor NT-proBNP has established superiority for early HF diagnosis; leaves open optimal biomarker selection pending direct comparative trials.
Because contemporary heart failure therapy has been shown significantly to reduce mortality and the number of hospital readmissions, an early and correct diagnosis is crucial. The clinical diagnosi...
No takes yet. Share an insight, caveat, or question.
Kragelund et al. (2005) studied this question. BNP and NT-proBNP are evaluated to determine which peptide is the better choice for the early clinical diagnosis of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: